Biovet, the veterinary division of Bharat Biotech, has introduced Biolumpivaxin, a cutting-edge vaccine created to counter Lumpy Skin Disease (LSD) in buffaloes and cattle. The vaccine was launched by Andhra Pradesh Chief Minister N. Chandrababu Naidu at the Livestock Prosperity Conclave organized in Vijayawada.

Key highlights

India's first DIVA marker vaccine against LSD

• Biolumpivaxin is the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine for LSD.

• It facilitates improved surveillance by differentiating between naturally infected and vaccinated animals.

• ICAR-NRCE and Biovet developed it using the LSD virus/Ranchi/2019 strain.

National impact and urgency

• India witnessed two severe LSD outbreaks—one in 2019 and another in 2022, with over 200,000 cattle lost.

• The disease also caused serious loss of milk production in affected areas.

• CDSCO has given market clearance to Biolumpivaxin in February 2025.

Vaccine regimen and storage

• The vaccine is given annually to cattle and buffaloes of all ages.

• Packaged in multi-dose vials (25 to 100 doses) and kept at 2–8°C.

• The production unit of Biovet in Bengaluru has a 500 million dose capacity, making it large-scale available.

Statements from leaders
"Every possible measure must be taken sincerely to facilitate proper distribution of the vaccine… to bring about the long-term viability of the dairy industry,"
– N. Chandrababu Naidu, Chief Minister, Andhra Pradesh"Livestock is one of our country's finest assets. This vaccine guards the dairy industry and enhances our Atmanirbhar Bharat vision,"
– Dr. Krishna Ella, Founder, Biovet and Executive Chairman, Bharat BiotechBiolumpivaxin is a giant step in India's animal health system, providing an efficient, scalable, and scientifically sophisticated solution to Lumpy Skin Disease. With national approval and large-scale production capacity, the vaccine has the potential to be a driving force in safeguarding India's dairy economy and livestock health.